In such regards, the METTEN prospective study was conducted on human epidermal growth factor receptor 2 positive (HER2 +) non-diabetic BC patients receiving trastuzumab and neoadjuvant chemotherapy in combination with metformin12. The gene discussed is ERBB2; the disease is breast cancer.